Dr. Riedel was executive chairman and chief executive officer of Apinyx. He was formerly president and CEO of Naurex, the predecessor company acquired by Allergan and from which Aptinyx and its technology were spun out. Prior to Naurex, Dr. Riedel served various roles at Baxter International including corporate vice president and chief science and innovation officer. Previously, he was head of worldwide biotechnology and held a number of scientific management positions at Hoechst Marion Roussel (now Sanofi).

Dr. Riedel serves on the board of Jazz Pharmaceuticals, Eton Pharmaceuticals, and the Illinois Biotechnology Innovation Organization. He served on the board of directors of Ariad Pharmaceuticals until the company was acquired in February 2017, and the board of Cerevel Therapeutics until the company was acquired in August of 2024.

Dr. Riedel is a member of the Austrian Academy of Sciences and served on Governor Pat Quinn’s Illinois Innovation Council. He is an adjunct professor at Boston University School of Medicine and Northwestern University’s Fienberg School of Medicine and, prior to moving into the industry, was an associate professor of medicines at Boston University School of Medicine and a visiting professor at the Massachusetts Institute of Technology.

Dr. Riedel received a Diplomar and PH.D. from the University of Frankfurt and was a postdoctoral fellow at Harvard University.